InO - A Retrospective Study of UK Patients With Leukaemia

  • STATUS
    Recruiting
  • participants needed
    25
  • sponsor
    Pfizer
Send
Updated on 16 February 2024
See if I qualify
lymphoma
leukemia
b-cell acute lymphoblastic leukemia
inotuzumab
lymphoblastic leukemia
acute lymphoblastic leukemia

Summary

The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.

Details
Condition childhood ALL
Age 18years - 100years
Treatment Inotuzumab Ozogamicin
Clinical Study IdentifierNCT04456959
SponsorPfizer
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients with relapsed/refractory ALL
Patients who initiated InO between 1st of June 2016 and date of data collection
Patients who accessed InO treatment via NHS commissioning, via the CUP, or via private purchase
Patient aged 18 years old at initiation of InO treatment

Exclusion Criteria

Patients initiated on treatment with InO at a different hospital than the ones selected in this study
Patients with <3 months of follow-up since index date, unless death occurs <3 months from index date
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

lymphoma
leukemia
b-cell acute lymphoblastic leukemia
inotuzumab
lymphoblastic leukemia
acute lymphoblastic leukemia

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.